Tokura, Y., Nakayama, Y., Fukada, S., Nara, N., Yamamoto, H., Matsuda, R., & Hara, T
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 Centers for Disease Control and Prevention
Frequently Asked Questions About MIC B12 Injections in West Edmonton, Alberta Learn More About Mens Health
Unlike a sanctioned clinical trial (where experimental drugs can be used under careful monitoring and informed consent under an FDA Investigational New Drug protocol), offering BPC-157 in routine practice amounts to experimenting on the patient without oversight